跳至主要内容
临床试验/NCT01463007
NCT01463007已完成不适用

ACCELERATED PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (ACCUBOOST) FOR EARLY STAGE BREAST CANCERS: A TOXICITY ASSESSMENT

Jaroslaw Hepel8 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2011年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
8
主要终点
Early and Intermediate Toxicity

研究概览

简要总结

The purpose of this study is to evaluate the rate of early and intermediate toxicity related to the AccuBoost System for delivery of APBI in women with resected, early stage breast cancer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • A confirmed histological diagnosis of invasive breast carcinoma or DCIS
  • Age greater or equal to 50 years old
  • Life expectancy > 6 months
  • Treated by breast conserving surgery with axillary node dissection or sentinel lymph node biopsy
  • Pathologic tumor size less than or equal to 2 cm
  • Invasive ductal, mucinous, tubular or colloid histology
  • Estrogen receptor positive for invasive carcinoma.
  • Unifocal/unicentric disease
  • Negative surgical margins greater than or equal to 2 mm
  • Pathologic lymph node negative
  • No evidence of lymphovascular invasion
  • ECOG performance status of 0 or 1 (Appendix 1)
  • Informed consent signed.

排除标准

  • Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required)
  • Autoimmune disorder
  • Breast implants
  • Psychiatric or addictive disorder that would preclude attending follow-up
  • Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted)
  • Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy proven benign)
  • Lobular features on histology (pure or mixed) or sarcoma histology
  • Node positive on axillary dissection or in the sentinel lymph node biopsy;
  • Extensive in situ carcinoma (EIC)
  • Multicentric or multifocal disease
  • Paget's disease of the nipple
  • Distant metastases
  • Lumpectomy cavity not well visualized on AccuBoost imaging
  • Lumpectomy cavity with 1cm margin (PTV) not adequately encompassed by any applicator (PTV > 6cm)
  • Breast separation with compression > 7cm.
  • Overlap of skin between orthogonal treatment axes.

结局指标

主要结局

Early and Intermediate Toxicity

时间窗: 2 years

Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (Appendix 4). Acute side effects are any side effects occurring within 3 months of treatment. Intermediate side effects are any side effects occurring between 3 months and 2 years. This is reported in the outcome table.

次要结局

  • Cosmetic Outcome(2 years)

研究者

发起方
Jaroslaw Hepel
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jaroslaw Hepel

principal investigator

Brown University

研究点 (8)

Loading locations...

相似试验